Celator Claims Phase III Vyxeos Victory In AML
This article was originally published in Scrip
Celator Pharmaceuticals Inc. more than quadrupled in after-hours trading on March 14 after the company reported Phase III overall survival (OS) data for Vyxeos (CPX-351) that could support US and EU approvals for the first new acute myeloid leukemia (AML) therapy in almost 40 years.
You may also be interested in...
With proof of concept for its CombiPlex platform in the form of Phase III results for Vyxeos in acute myeloid leukemia, the $1.5bn purchase price paid by Jazz bought more than a promising late-stage asset.
The ASCO abstracts are out – and with them a scramble to see exactly what will be hitting the headlines in early June. Here, with the help of Sagient's BioMedTracker, Scrip takes a look at some of the more interesting studies due to be presented in Chicago in a couple weeks.
Private Company Edition: Scrip spoke with DDF US partner Jonathan Behr about the convergence of emerging science, venture capital investment and rising big pharma interest in neurodegeneration. Also, in recent VC financings HotSpot raised $100m, while Curie and Ablaze debuted with $75m each.